Discovery and Verification of Multi-component Chinese Medicine with Anti-tumor Activity from Shuanghuanglian

Pei-huang WEI; Wei ZHANG; Cheng LI; Shi-ying TAO; Cheng-ke CAI; Qiang LI; Jian LI

doi:10.13422/j.cnki.syfjx.20201523

您当前的位置：

首页 >

文章列表页 >

Discovery and Verification of Multi-component Chinese Medicine with Anti-tumor Activity from Shuanghuanglian

Pharmacology | 更新时间：2020-08-11

- Discovery and Verification of Multi-component Chinese Medicine with Anti-tumor Activity from Shuanghuanglian
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 15, Pages: 69-74(2020)
- 作者机构：
  
  北京中医药大学，北京 100029
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201523
  CLC： R22;R242;R2-031;R285.5
- Published Online：22 May 2020，
  
  Published：05 August 2020
- 稿件说明：
移动端阅览
魏佩煌,张玮,李城等.双黄连抗结肠癌活性组分中药的发现和验证[J].中国实验方剂学杂志,2020,26(15):69-74.

WEI Pei-huang,ZHANG Wei,LI Cheng,et al.Discovery and Verification of Multi-component Chinese Medicine with Anti-tumor Activity from Shuanghuanglian[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(15):69-74.
魏佩煌,张玮,李城等.双黄连抗结肠癌活性组分中药的发现和验证[J].中国实验方剂学杂志,2020,26(15):69-74. DOI： 10.13422/j.cnki.syfjx.20201523.

WEI Pei-huang,ZHANG Wei,LI Cheng,et al.Discovery and Verification of Multi-component Chinese Medicine with Anti-tumor Activity from Shuanghuanglian[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(15):69-74. DOI： 10.13422/j.cnki.syfjx.20201523.

摘要

目的

应用网络药理学方法，从双黄连方剂中预测具有抗肿瘤活性的组分中药，并通过离体细胞实验与动物实验对其抗CT26结肠癌活性进行初步验证。

方法

基于中药系统药理学数据库（Traditional Chinese Medicine Systems Pharmacology Database，TCMSP），《中药活性成分分析手册》，药品生物信息学和化学信息学数据库（DrugBank），信号通路数据库（Reactome）及人类蛋白质参考数据库（Human protein reference database，HPRD），构建蛋白-蛋白相互作用网络（protein-protein interactions network， PPI）和化合物靶标网络，挖掘化合物的药理作用，发现与PPI网络节点距离较短的化合物，确定组成中药的配伍。以CT26结肠癌细胞为实验材料，结合离体和在体实验初步验证组分中药的抗肿瘤作用。

结果

从双黄连组分中预测并发现“黄芩苷、连翘酯苷A和绿原酸”3个化合物配伍具有潜在抗肿瘤活性。验证结果表明，细胞实验中，与空白组比较，双黄连组分中药能显著抑制CT26细胞的增殖和迁移（

0.01）；动物实验中，与荷瘤模型组比较，双黄连组分中药治疗组小鼠皮下肿瘤体积增长缓慢、肿瘤重量显著降低（

0.01）。

结论

结合数据库挖掘和化合物靶点网络构建、分析等方法从双黄连方剂中发现具有抗肿瘤活性的组分中药“黄芩苷、连翘酯苷A和绿原酸”。经验证，该组分中药具有较好的抗CT26结肠癌活性。

Abstract

Objective

The methods of network pharmacology were adopted to predict Multi-component Chinese Medicine （MCCM） with anti-tumor activity from Shuanghuanglian （SHL）. Furthermore， the pharmaceutical activity of CT26 colon cancer was verified

in vitro

and

in vivo

Method

Based on the Traditional Chinese Medicine Systems Pharmacology Database （TCMSP）， the Handbook of Active Components Analysis of Traditional Chinese Medicine， the Drugbank database， the Reactome database， and the Human protein reference database （HPRD）， the protein-protein interactions network （PPI） and the drug target network were built and resolved. The data was mined to discover the pharmacological effect. The anti- tumor activity of components from SHL was determined based on the nearest distance rule between the compounds and the nodes of network. And then， the anti-tumor effect of the MCCM was verified

in vitro

and

in vivo

Result

The 3 combined compounds， baicalin， forsythoside A and chlorogenic acid with the anti-tumor activity from SHL were predicted and discovered. The verification results showed that the combination of baicalin-forsythoside A-chlorogenic acid could significantly inhibit the cell proliferation and migration compared with the control group

in vitro

（

0.01）. Among CT26 bearing mice， the tumor volume and weight were significantly decreased after the combined administration of baicalin-forsythoside A-chlorogenic acid compared with the model group

in vivo

（

0.01）.

Conclusion

By the methods of network pharmacology， the anti-tumor activities of component of from SHL were discovered. According to the verification

in vitro

and

in vivo

， the combination of baicalin-forsythoside A-chlorogenic acid could play better anti-CT26 tumor activity.

关键词

Keywords

references

李慧，于晓晴，底建辉，等 . 双黄连颗粒联合阿奇霉素治疗儿童支原体肺炎临床研究［J］. 中国药业， 2019 ， 28 （ 8 ）： 27 - 29 .

付海生，熊向菁，王青海 . 雾化吸入双黄连注射液对慢性扁桃体炎的疗效及IL-6、hs-CRP和TNF- α 水平的影响［J］. 中华中医药学刊， 2019 ， 37 （ 2 ）： 392 - 395 .

孙效珍，解建设，解鲁豫 . 双黄连的药理与临床应用［J］. 黑龙江医药， 2006 ， 19 （ 1 ）： 54 - 55 .

韩森，李城，魏佩煌，等 . 注射用双黄连诱发肥大细胞脱颗粒的早期生物学效应［J］. 环球中医药， 2018 ， 11 （ 6 ）： 842 - 845 .

GAO X Y ， GUO M X ， LI Q ， et al . Plasma metabolomic profiling to reveal antipyretic mechanism of Shuang-huang-lian injection on yeast-induced pyrexia rats ［J］. PLoS One ， 2014 ， 9 （ 6 ）： 100 - 117 .

张旗，苏浬，汤明杰，等 . 双黄连粉针剂的化学成分研究［J］. 中医药学报， 2014 ， 42 （ 1 ）： 12 - 15 .

李静，岳淑梅，李健，等 . 文本挖掘注射用双黄连不良反应的相关因素［J］. 中国药事， 2013 ， 27 （ 11 ）： 1213 - 1217 .

张旗，崔秀荣，马海波，等 . 双黄连冻干粉针剂不良反应的研究进展［J］. 世界中医药， 2013 ， 8 （ 3 ）： 357 - 359 .

ZHANG B X ， LI J ， GU H ， et al . Using bioinformatics approach to explore the pharmacological mechanisms of multiple ingredients in Shuang-Huang-Lian ［J］. Sci World J ， 2015 ， 291 （ 680 ）： 352 - 356 .

曹子丰，唐德才，时晓霞，等 . 黄芪、莪术配伍联合奥沙利铂对CT26.WT原位移植瘤小鼠中CXCR3、CCR6表达影响［J］. 北京中医药大学学报， 2017 ， 40 （ 6 ）： 477 - 482 .

陈亚红，刘传鑫，何涛，等 . 丹参饮治疗糖尿病心肌病的网络药理学研究［J］. 中草药， 2019 ， 50 （ 5 ）： 1164 - 1174 .

顾浩，王耘，肖斌，等 . 中药功效-药性组合关联关系研究［J］. 时珍国医国药， 2011 ， 22 （ 7 ）： 1568 - 1571 .

张伯礼，王永炎 . 方剂关键科学问题的基础研究——以组分配伍研制现代中药［J］. 中国天然药物， 2005 ， 3 （ 5 ）： 258 - 261 .

刘丽梅，张俊华，岳广欣，等 . 组分中药产生背景回顾及未来展望［J］. 中国中医药信息杂志， 2016 ， 23 （ 5 ）： 1 - 5 ．

侯天将，由凤鸣，严然，等 . 浅谈中医肿瘤的共性病机及治法［J］. 四川中医， 2016 ， 34 （ 7 ）： 46 - 48 .

张俊华，樊官伟，张晗，等 . 组分中药理论的发展与应用［J］. 中国中药杂志， 2017 ， 42 （ 21 ）： 4054 - 4058 .

王雪雁，杨柱，龙奉玺，等 . 浅谈清热解毒治则治法在肿瘤疾病中的运用［J］. 中医药临床杂志， 2018 ， 30 （ 8 ）： 1409 - 1412 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Application of Anti-tumor Compatibility Structure of Chinese Medicine

Anti-tumor Mechanism of Traditional Chinese Medicine with Effect of Softening Hardness and Dissipating Mass： A Review

Network Correlation Analysis Between Components of Shuanghuanglian Injection and Allergy-like Targets

Antioxidant and Anti-tumor Effect and Mechanisms of Andrographis paniculata Polysaccharide on Human Cervical Cancer HeLa Cells

Research Progress in Extraction Technology， Structural Characteristics and Pharmacological Activities of Hippophae rhamnoides Polysaccharides

Related Author

CHEN Lanpin

TAN Feng

WEI Xiaoman

WANG Junyi

LI Liu

WU Mianhua

CHENG Haibo

SUN Dongdong

Related Institution

The Affiliated Hospital of Nanjing University of Chinese Medicine

Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine for Tumor Prevention and Treatment

The First School of Clinical Medicine of Nanjing University of Chinese Medicine

School of Clinical Medicine of Nanjing University of Chinese Medicine

Guang'anmen Hospital， China Academy of Chinese Medical Sciences

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰